Drugs News and Research

RSS

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Isis Pharmaceuticals, Inc. today announced its 2009 financial results and reviewed the highlights of the year. Isis achieved its 2009 financial guidance with pro forma net income of $166.9 million and a pro forma net operating loss (NOL) of $14.2 million compared with its guidance for the year of pro forma net income of more than $145 million and a pro forma NOL in the low to mid $20 million range. Isis also achieved its cash guidance by ending 2009 with $574.3 million of cash, cash equivalents and short-term investments significantly in excess of the $550 million projected.

1 Mar 2010

Researchers figure out how ATP molecule broken down in cells

Researchers at the Louisiana State University Health Sciences Center have figured out how ATP is broken down in cells, providing for the first time a clear picture of the key reaction that allows cells in all living things to function and flourish.

1 Mar 2010

Pi2 Solutions introduces 2010 version of Product Literature Database System

Pi2 Solutions announces the all-new 2010 version of their world-leading Product Literature Database System. This versatile application builds on the success of the 2003 version in use in biopharmaceutical companies around the globe.

1 Mar 2010

Ipsen’s 2009 performance: Azzalure, Dysport and Decapeptyl approval, Adenuric partnership, drug sales up 7.6%

The Board of Directors of Ipsen, chaired by Jean-Luc Bélingard, met on 26 February 2010 to review the Group’s results for 2009, published today.

1 Mar 2010

Aprepitant drug can reduce nausea and vomiting when combined with other anti-nausea drugs

Bone marrow transplant patients say two of the most debilitating side effects of the treatment are nausea and vomiting caused by chemotherapy and radiation.

1 Mar 2010

NPS Pharmaceuticals supports second annual U.S. Rare Disease Day observance

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today its support for the second annual U.S. Rare Disease Day observance on February 28.

1 Mar 2010

Regular use of aspirin, acetaminophen and NSAIDs increases risk of hearing loss in men

In a study published in the March 2010 issue of The American Journal of Medicine, researchers determined that regular use of aspirin, acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) increases the risk of hearing loss in men, particularly in younger men, below age 60.

1 Mar 2010

ADMET tester Absorption Systems joins Society of Toxicology as Affiliate

Absorption Systems, a leader in testing drugs for ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity), has joined the Society of Toxicology, the premier global professional association of toxicologists, as an SOT Affiliate. The firm, a contract research organization, has more than a decade of experience assisting pharmaceutical and biotechnology companies in determining which compounds in development should be advanced into clinical testing.

27 Feb 2010

Of the 2.3M inmates, only 1.5M meet DSM IV medical criteria for substance abuse: CASA

Of the 2.3 million inmates crowding our nation's prisons and jails, 1.5 million meet the DSM IV medical criteria for substance abuse or addiction, and another 458,000, while not meeting the strict DSM IV criteria, had histories of substance abuse; were under the influence of alcohol or other drugs at the time of their crime; committed their offense to get money to buy drugs; were incarcerated for an alcohol or drug law violation; or shared some combination of these characteristics, according to Behind Bars II: Substance Abuse and America's Prison Population. Combined these two groups constitute 85 percent of the U.S. prison population.

27 Feb 2010

Electronic prescribing decreases prescription errors

Should doctors around the country use e-prescribing to decrease prescription errors? A study led by physician-scientists from Weill Cornell Medical College found that health care providers using an electronic system to write prescriptions were seven times less likely to make errors than those writing their prescriptions by hand. The study appears today in the online edition of the Journal of General Internal Medicine.

27 Feb 2010

Two Atlanta-based nursing homes and their principals to pay the U.S. and several states $14M

Atlanta-based Mariner Health Care Inc. and SavaSeniorCare Administrative Services LLC, as well as their principals, Leonard Grunstein, Murray Forman and Rubin Schron, have agreed to pay the United States and several states $14 million, the Justice Department announced today.

27 Feb 2010

New cooling method uncovers inner workings of key iron-containing enzyme

A team of Michigan State University scientists -- using a new cooling method they created - have uncovered the inner workings of a key iron-containing enzyme, a discovery that could help researchers develop new medicines or understand how enzymes repair DNA.

27 Feb 2010

State roundup: S.C. plan would end benefits to 30,000 disabled residents; Judge bars Calif. from cutting elderly from day care; Mass. faces lawsuit on immigrant health care

Children with autism, people with spine and brain injuries and the long-term disabled in job programs are among the 30,000 people who would lose state help under a $5.1 billion spending plan approved by a House committee Thursday.

27 Feb 2010

Neurogenesis linked to drug addiction and relapse

Researchers at UT Southwestern Medical Center hope they have begun paving a new pathway in the fight against drug dependence. Their hypothesis - that increasing the normally occurring process of making nerve cells might prevent addiction - is based on a rodent study demonstrating that blocking new growth of specific brain nerve cells increases vulnerability for cocaine addiction and relapse.

27 Feb 2010

Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I. Shapiro of Dana-Farber Cancer Institute, presented preclinical and clinical data on STA-9090, a potent second-generation Hsp90 inhibitor, at IASLC (International Association for the Study of Lung Cancer) 10th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting in Santa Monica, CA.

27 Feb 2010

Dabigatran as effective as warfarin in preventing subsequent strokes among atrial fibrillation patients

The drug dabigatran was as effective as the currently recommended drug – warfarin – in preventing a subsequent stroke among people with atrial fibrillation and prior stroke or transient ischemic attack – and it did so with less bleeding according to late-breaking science presented at the American Stroke Association's International Stroke Conference 2010.

27 Feb 2010

Cancer researchers assess PCI-32765 drug that targets molecular abnormalities of lymphoma cells

Cancer researchers have high hopes for a new therapy for patients with certain types of lymphoma and leukemia.

27 Feb 2010

Prevention of recurrent strokes: Antiplatelet drug cilostazol effective and safer than aspirin

The antiplatelet drug cilostazol — used in the United States to treat leg pain associated with peripheral vascular disease — was more effective and safer than aspirin at preventing recurrent strokes in a Japanese trial presented as late-breaking science at the American Stroke Association's International Stroke Conference 2010.

27 Feb 2010

Notch-blocking drug effective against brain cancer stem cells, but more than one targeted attack needed

Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells - a small population of cells within tumors that perpetuate cancer growth - conclude that blocking these cells may be somewhat effective, but more than one targeted drug attack may be needed to get the job done.

26 Feb 2010

Librede to develop technologies for improving ion channel drug discovery and screening at CNSI incubator

Librede Inc. has joined the UCLA on-campus technology incubator space at the California NanoSystems Institute, where the startup company will work on developing technologies to improve ion channel drug discovery and screening.

26 Feb 2010

Drugs News and Research

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Researchers figure out how ATP molecule broken down in cells

Pi2 Solutions introduces 2010 version of Product Literature Database System

Ipsen’s 2009 performance: Azzalure, Dysport and Decapeptyl approval, Adenuric partnership, drug sales up 7.6%

Aprepitant drug can reduce nausea and vomiting when combined with other anti-nausea drugs

NPS Pharmaceuticals supports second annual U.S. Rare Disease Day observance

Regular use of aspirin, acetaminophen and NSAIDs increases risk of hearing loss in men

ADMET tester Absorption Systems joins Society of Toxicology as Affiliate

Of the 2.3M inmates, only 1.5M meet DSM IV medical criteria for substance abuse: CASA

Electronic prescribing decreases prescription errors

Two Atlanta-based nursing homes and their principals to pay the U.S. and several states $14M

New cooling method uncovers inner workings of key iron-containing enzyme

State roundup: S.C. plan would end benefits to 30,000 disabled residents; Judge bars Calif. from cutting elderly from day care; Mass. faces lawsuit on immigrant health care

Neurogenesis linked to drug addiction and relapse

Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090

Dabigatran as effective as warfarin in preventing subsequent strokes among atrial fibrillation patients

Cancer researchers assess PCI-32765 drug that targets molecular abnormalities of lymphoma cells

Prevention of recurrent strokes: Antiplatelet drug cilostazol effective and safer than aspirin

Notch-blocking drug effective against brain cancer stem cells, but more than one targeted attack needed

Librede to develop technologies for improving ion channel drug discovery and screening at CNSI incubator

Drug Discovery - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News